Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease

Katharina Schwarzkopf, Joerg Bojunga, Sabrina Rüschenbaum, Yolanda Martinez, Marcus M. Mücke, Florian Seeger, Fabian Schoelzel, Stefan Zeuzem, Mireen Friedrich‐Rust, Christian M. Lange – 5 October 2018 – Platelets participate in the development of liver fibrosis in animal models, but little is known about the benefit of antiplatelet agents in preventing liver fibrosis in humans. We therefore explored the relationship between the use of antiplatelet agents and liver fibrosis in a prospective cohort study of patients at high risk of liver fibrosis and cardiovascular events.

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4

Daniel H. Leung, Stefan Wirth, Betty B. Yao, Rolando M. Viani, Regino P. Gonzalez‐Peralta, Maureen M. Jonas, Steven J. Lobritto, Michael R. Narkewicz, Etienne Sokal, Clàudia Fortuny, Evelyn K. Hsu, Antonio Del Valle‐Segarra, Jiuhong Zha, Lois Larsen, Li Liu, Diana L. Shuster, Daniel E. Cohen, Philip Rosenthal – 5 October 2018 – In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates of sustained virologic response (SVR).

Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States

Haesuk Park, Wei Wang, Linda Henry, David R. Nelson – 5 October 2018 – Approved treatment for hepatitis C virus (HCV) with all‐oral direct‐acting antivirals (DAA) therapy is now entering into its fourth year; however, little has been reported on the real‐world clinical (decompensated cirrhosis [DCC] and hepatocellular carcinoma [HCC]) and economic outcomes. A retrospective cohort analysis of the Truven Health MarketScan Database (2012‐2016) was conducted.

Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis

Silvia Nardelli, Stefania Gioia, Lorenzo Ridola, Alessio Farcomeni, Manuela Merli, Oliviero Riggio – 5 October 2018 – Minimal hepatic encephalopathy (MHE) is a subclinical cognitive impairment frequently observable in patients with cirrhosis. Proton pump inhibitors (PPIs) can contribute to small‐bowel bacterial overgrowth, but no study has investigated the link between PPIs and MHE. We investigated the relationship between MHE and PPI use as well as the role of PPI use in the development of overt HE and survival.

Subscribe to